• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , June 4

LEE Pharma (P) Ltd has claimed that it has won a patent infringement case against Eli Lilly & Company.

The Rs 33-crore company is into manufacture of drugs in various therapeutic categories and claims strengths in specialisation of modified release dosage forms of various pellets and granules. It is currently exporting its pellets to around 25 countries in the global market.

In a press release here, the company said the patent case pertained to olanzapine, the generic version of Eli Lilly's patented drug Zyprexa, indicated for the treatment of Schizophrenia. The Patent Office in Lima, Peru has rejected the claims of Eli Lilly about infringing process of olanzapine form-I.

The company said the success came about through representation by its marketing partner for Latin America, Micro Labs, based in Bangalore, which filed the dossier to launch its olanzapine form - I formulation in Latin America.

According to the Lee Pharma Managing Director, Mr A. Venkat Reddy, Eli Lilly filed a case against Micro Labs in Peru stating that the latter's product was infringing the process.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Premier Auto launches 2 new vehicles in Kerala

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line